Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity
Date
2021
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
American Medical Association
Abstract
This study determines which of 8 doses of bevacizumab are effective in treating severe retinopathy of prematurity to carry forward to a large-scale randomized clinical trial.
Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Kraker RT, Wallace DK, Beck RW, et al. Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity. JAMA Ophthalmol. 2021;139(10):1143-1144. doi:10.1001/jamaophthalmol.2021.3192
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
JAMA Ophthalmology
Rights
Publisher Policy
Source
PMC
Alternative Title
Type
Article